Dr. Mukesh Parmar is a distinguished researcher specializing in the synthesis of therapeutically active compounds. His work primarily focuses on the development of bioactive molecules and metal complexes.
In addition to his research endeavors, Dr. Parmar has held notable positions in the industry. He served at various company to central government lab. In his role, he was responsible for method development, validation, and analysis of antibiotics, heavy metals, dyes, and histamine, adhering to European Union standards. His duties also encompassed calibration, maintenance, and troubleshooting of sophisticated instruments along with supervising and training laboratory staff. Dr. Parmar's expertise extends to various analytical techniques, including ICP-MS, LC-MSMS, GC-MSMS, GC-FID, HPLC-UV, XRF, AAS and UV-Vis spectrophotometer which he masters during his job.
Presently working as Technical Manager & Team leader (FEPAS Division) at envitro laboratories pvt ltd.
His scholarly contributions are documented in several publications, including:
- "A brief review on imidazole, triazine, and isatin derivatives: synthesis approaches and their applications" (November 2024), which provides a comprehensive overview of these compounds' synthesis methods and potential pharmaceutical applications.
- "Synthesis, Characterization and Biological Evaluation of Various 1H-imidazol Derivatives" (February 2024), detailing an efficient approach to synthesizing substituted 1H-imidazol analogues.
- "Synthesis, Characterization of Various Substituted (E)-2-(2-butyl-5-chloro-4-((phenylimino)methyl)-1H-imidazol-1-yl)-N-(4-(3-oxomorpholino)phenyl)acetamide" (May 2023), discussing the synthesis of specific imidazole derivatives.
.jpeg)
